Wells Fargo & Company Werewolf Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
A detailed history of Wells Fargo & Company transactions in Werewolf Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 194 shares of HOWL stock, worth $527. This represents 0.0% of its overall portfolio holdings.
Number of Shares
194
Previous 154
25.97%
Holding current value
$527
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding HOWL
# of Institutions
64Shares Held
26.1MCall Options Held
2.4KPut Options Held
35K-
Mpm Asset Management LLC Cambridge, MA4.28MShares$11.7 Million11.32% of portfolio
-
Pfm Health Sciences, LP San Francisco, CA3.01MShares$8.18 Million0.96% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3MShares$8.16 Million0.04% of portfolio
-
Bio Impact Capital LLC Cambridge, MA2.39MShares$6.5 Million2.53% of portfolio
-
Bank Of America Corp Charlotte, NC1.88MShares$5.12 Million0.0% of portfolio
About Werewolf Therapeutics, Inc.
- Ticker HOWL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,529,400
- Market Cap $80.3M
- Description
- Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional ...